A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

NCT00686075 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

1338

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

BIOLOGICAL: MEDI-534, Cohort 1
OTHER: Placebo, Cohort 1
BIOLOGICAL: MEDI-534, Cohort 2
OTHER: Placebo, Cohort 2
BIOLOGICAL: MEDI-534, Cohort 3
OTHER: Placebo, Cohort 3
BIOLOGICAL: MEDI-534, Cohort 4
OTHER: Placebo, Cohort 4
BIOLOGICAL: MEDI-534, Cohort 5
OTHER: Placebo, Cohort 5

Sponsor

MedImmune LLC